These are life-altering medicines with weight loss now comparable to surgical weight loss.” These medicines not only improve diabetes but also decrease (the) risk of stroke, heart attack, and chronic kidney damage. “They also have anti-inflammatory effects, protect nervous system inflammation, and decrease fatty liver deposits. “Their mechanism of actions are more or less similar and act on (the) brain causing loss of appetite or satiety, and on the stomach causing decreased emptying,” Dr. Jeffrey Kraft, bariatric surgeon with Hackensack University Medical Center in Hackensack, NJ, explained to MNT. “Where Zepbound differs slightly is that it also imitates a second hormone, called GIP (glucose-dependent insulinotropic polypeptide), which, along with reducing appetite, may also improve how the body breaks down sugar,” Dr. However, Zepbound also activates a second hormone receptor. Alexander added.Īll four of these medications are glucagon-like peptide-1 (GLP-1) receptor agonists, which helps with blood sugar control. “They replace hormones in our weight regulatory system that are deficient or resistant causing weight dysregulation resulting in overweight and obesity,” Dr. Alexander, chief medical officer of Enara Health and president-elect of the Obesity Medicine Association explained to MNT, Wegovy, Ozempic, Mounjaro, and Zepbound are all types of hormone replacement therapy. The average starting weight for a study participant was 231 lbs.Ĭomparing Zepbound with Mounjaro, Wegovy, and OzempicĪccording to Dr. Kuldeep Singh, director of the Maryland Bariatric Center at Mercy Medical Center in Baltimore, MD - who was not involved in this study - told Medical News Today. “In comparison, surgical weight loss typically causes 30-35% total body weight loss,” Dr. The studies also found that one in three participants taking Zepbound at the highest dose lost over 58 lbs or 25% of their body weight. Through these studies, researchers reported that over 72 weeks, participants who took the highest dose of Zepbound lost an average of 48 lbs, and those who took the lowest dose lost an average of 34 lbs. The FDA approval of Zepbound is based on the results of the SURMOUNT-1 and SURMOUNT-2 phase 3 clinical trials. This new weight loss drug is for adults who are obese with a body mass index (BMI) of 30 kg/m2 or greater or those who are overweight with a BMI of 27 kg/m2 or greater and who also have a weight-related medical issue.Īdditionally, the medication should be used with a reduced-calorie diet and increased physical activity. Zepbound and Mounjaro share the same active ingredient called tirzepatide. They are also the makers of type 2 diabetes medication Mounjaro. Zepbound is an obesity treatment made by Eli Lilly and Company.

Mercy medical center sleep center